The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer treatment for patients who received endocrine therapy but are not suitable for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback